FROM A-LEVELS OR AN OVERSEAS DEGREE TO PRACTISING IN THE UKSearch the guide
← All news
NEW MEDICINES AND DRUG DISCOVERY · MHRA (UK MEDICINES REGULATOR) · 26 October 2026

Class 2 Medicines Recall: Xeal Pharma, Clopidogrel Oral Liquids (all strengths), EL(26)A/43

Synopsis

Xeal Pharma have informed MHRA that all strengths of their Clopidogrel Oral Suspension and Clopidogrel Oral Solution products contain less than the labelled amount of clopidogrel. Xeal Pharma have informed MHRA that all strengths of their Clopidogrel Oral Suspension and Clopidogrel Oral Solution products contain less than the labelled amount of clopidogrel.

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.

Read the full story at MHRA (UK medicines regulator) ↗

More in New medicines and drug discovery